GAPVAC-101: personalized vaccines for newly-diagnosed glioblastoma

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Wolfgang Wick, MD, of the German Cancer Research Center, Heidelberg, Germany, discusses GAPVAC-101 (NCT02149225), the first-in-human trial of a highly personalized peptide vaccination for patients with newly diagnosed gliobastoma. The investigations have demonstrated that the Actively Personalized Vaccines (APVACS) vaccines are generally well tolerated, with only a few patients suffering adverse reactions, such as local dermal reactions to the immune stimulants and brain edema. Further investigations may lead to the development of new blueprints for trials in personalized medicine in the future.